Key result
CYP2C19 polymorphic alleles occur in 25% of Colombian ACS patients experiencing adverse reactions to clopidogrel.
Why the study?
Interindividual variability in clopidogrel response is attributed to CYP2C19 variants, but data in ethnically heterogeneous and poorly studied populations are limited.
What are the allele frequencies of CYP2C19 variants and their association with adverse drug reactions in Colombian patients with acute coronary syndrome treated with clopidogrel?
Observational (n=166)
What are the allele frequencies of CYP2C19 variants and their association with adverse drug reactions in Colombian patients with acute coronary syndrome treated with clopidogrel?
The study identifies new potentially pathogenic mutations and regulatory variants in CYP2C19 that may influence clopidogrel response and bleeding risk in Colombian patients with ACS.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for CYP2C19 variants in Colombian ACS patients; prospective trials needed before clinical adoption.
Clopidogrel, an oral platelet P2Y12 receptor blocker, is used in the treatment of acute coronary syndrome. Interindividual variability in treatment response and the occurrence of adverse effects has been attributed to genetic variants in CYP2C19. The analysis of relevant pharmacogenes in ethnically heterogeneous and poorly studied populations contributes to the implementation of personalized medicine. We analyzed the coding and regulatory regions of CYP2C19 in 166 patients with acute coronary syndrome (ACS) treated with clopidogrel. The allele frequencies of CYP2C19 alleles *1, *2, *4, *17, *27 and *33 alleles were 86.1%, 7.2%, 0.3%, 10.2%, 0.3% and 0.3%, respectively. A new potentially pathogenic mutation (p.L15H) and five intronic variants with potential splicing effects were detected. In 14.4% of the patients, a new haplotype in strong linkage disequilibrium was identified. The clinical outcome indicated that 13.5% of the patients presented adverse drugs reactions with a predominance of bleeding while 25% of these patients were carriers of at least one polymorphic allele. We propose that new regulatory single-nucleotide variants (SNVs) might potentially influence the response to clopidogrel in Colombian individuals.
No takes yet. Share an insight, caveat, or question.
Angulo-Aguado et al. (2021) conducted an observational in Acute coronary syndrome (n=166). Clopidogrel was evaluated on Adverse drug reactions (predominantly bleeding). Pharmacogenetic analysis of CYP2C19 in Colombian ACS patients treated with clopidogrel revealed that 13.5% experienced adverse drug reactions, of which 25% carried at least one polymorphic allele.
Synapse has enriched 10 related papers. Consider them for comparative context: